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1. INTRODUCTION AND BACKGROUND 
 
1.1 The population of cancer survivors is growing  
In Norway, a country with roughly 5.3 million inhabitants, nearly 33 000 new cancer incidents 
are reported each year, moreover approximately 262 000 prevalent cancer patients were 
reported alive at the end of 20161. For testicular cancer (TC), the worldwide incidence has 
doubled during the past four decades, and TC is now the most prevalent solid tumor in men 
between 15 and 34 years of age2,3. The improvement in TC survival increased rapidly during 
the 1970s due to the introduction of cisplatin therapy for advanced germ cell tumors (GCT), 
leading to a greatly improved prognosis for testicular cancer. Since we today consider TC as a 
highly curable malignant disease (Figure 1), the prevalence is rising, and in 2016 close to 7500 
Norwegian testicular cancer survivors (TCSs) were registered.  
Figure 1. Age-adjusted incidence, mortality and survival rates of testicular cancer, from 




As most TCSs are young at diagnosis, they may live for another 30-50 years after successful 
treatment for TC. Consequently, the number of long-term TCSs are growing steadily, which in 
turn has led to an increasing interest in the long-term side-effects of cancer therapy.  
Numerous studies focusing on TCSs have identified increased risks for several long-
term and late effects associated with cisplatin-based chemotherapy (CBCT), such as 
cardiovascular disease (CVD), hypertension (HT), ototoxicity, Raynaud’s phenomenon, 
peripheral neuropathy, decreased renal function, decreased pulmonary function, sexual 
dysfunction, reduced endocrine gonadal function, obesity and hypercholesterolemia4-15. High 
levels of residual serum platinum (Pt) have been measured in several long-term follow-up 
studies after CBCT, and up to 10% of the retained Pt species has been demonstrated to remain 
its activity16-18. A relationship between retained Pt and the development of late effects has been 
hypothesized16,19-21.  
Treatment burden and some genetic polymorphisms22 are currently the only identified 
risk factors associated with particularly high risk for long-term effects in TC patients after 
CBCT. When this study was initiated, a few reports had demonstrated that Pt was measurable 
in serum several years after treatment with CBCT17,23. However, only one study had evaluated 
the association between Pt and long-term effects (neuro- and ototoxicity)16. Further research to 
clarify associations between long-term Pt and late effects in TCS was recommended24. Thus, 
increased awareness and knowledge regarding long-term CBCT-related toxicity and its related 






1.2 Epidemiology and risk factors for testicular cancer 
The TC incidence is highest in the Northern parts of Europe and North-America and lowest in 
Asia and Africa3,25. In Denmark and Norway, almost 1% of males are diagnosed with a TC 
during their life-time2,3,26, and these countries have the highest worldwide incidence rates. In 
total, 285 men were diagnosed with TC in Norway in 2016, corresponding to an age-adjusted 
incidence rate at 10.7 per 100 0001. This rate is almost tripled compared to the registered rate 
during the 1960s. But even though the incidence rates are increasing in most European countries 
(Figure 2), the mortality rates are declining3. 





Although TC is not a frequent malignancy overall, it is the most common cancer among 15-49 
year old males. TC has the lowest median age at diagnosis of all cancers among adults (36 
years)1. Only 11% of Norwegian males diagnosed with TC in the period 2012-2016 were older 
than 50 years1.  
The overall cancer specific 10-year survival for non-seminomatous germ cell tumor 
(NSGCT) in Norway is currently 95%, and roughly 67% among poor-prognosis patients27. 
Today, no other malignancies have cure rates which can compete with TC, and TCSs have life 
expectancies almost similar to healthy age-matched men28,29.  
Since the incidence of TC has increased steadily during the last decades, a possible 
relationship with increased exposure to carcinogens from the environment has been implied, 
but the causes and mechanisms of TC development are still not well understood. Yet, the 
strongest known risk factors for TC are a previously diagnosed TC, a family history of TC and 
cryptorchidism30-32.  
In a Norwegian study with roughly 2000 TCSs treated during 1953-1990, the cumulative 
risk of developing a second germ cell cancer after 15 years was 5% and 3.4% for non-
seminomas and seminomas, respectively32.  The risk for a second germ cell cancer diagnosis is 
thus significantly higher than the initial TC risk in the general population, with a cumulative 
risk of roughly 1%. 
Family studies have shown that sons and siblings of TC patients have a 4-6-fold and 8-
10-fold increased TC risk, respectively33. The remarkably high risk within these families might 
represent the impact of shared genes or similar childhood environment. The combination of 
several susceptible genes has been hypothesized to contribute to the development of TC. 
However, the rapid increase in TC incidence and the fact that sons develop TC at younger age 
than their TC affected fathers, underscores the added effect from environmental factors, as the 
genetic composition in the population is not believed to change during a few generations only34. 
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The fact that siblings have a greater risk of TC development than sons of TC patients, indicates 
a possible effect of environmental disruptors in addition to genetic factors.  
Increasing adult height is associated with testicular cancer35, and the lifetime risk of 
having TC follows a typical birth cohort pattern36, implying that the causative factors for TC 
initiate their effect in utero or early in life. The TC risk among first-generation immigrants 
reflects the risk in the country of origin. On the other hand, second-generation immigrants have 
a risk close to the level observed among natives in their new country37. Taken together, 
environmental influences early in life are believed to increase the TC risk. Other less significant 
risk factors include testicular atrophy, infertility, inguinal hernia, hydrocele and other disorders 
of male sexual differentiation38. The association between TC risk and testicular developmental 
problems, such as infertility and testicular maldescent, have led to the theory of a “testicular 
dysgenesis syndrome” (TDS)38,39, where TC is the most serious manifestation of this syndrome 
(Figure 3).  





This feature has been hypothesized to originate in utero, and both environmental, 
genetic and epigenetic factors as well as lifestyle factors are probably involved40. Accumulating 
evidence suggest that changes in the hormonal ambience, and particularly increasing estrogen 
exposure, are linked to TDS and a rising incidence of TC41.  
 
1.4 Malignant germ cell tumors (GCTs) 
GCTs account for approximately 95% of all malignant tumors in the testes. The remaining 
tumors are composed of sex-cord tumors, lymphomas or metastases, and will not be further 
discussed in this thesis. Testicular GCTs are histopathologically classified into two groups, 
seminomas and non-seminomas42, both derived from a pre-invasive germ cell neoplasia in situ 
(GCNIS), which originates from transformed fetal gonocytes. Overall, at the time of diagnosis, 
about 25% of men with GCT have metastases43. 
Pure seminomas normally affect men in their thirties and forties. Unlike non-
seminomas, the majority of men with seminomas have tumors localized to the testis at 
presentation (about 85%)44, and rarely have metastasis beyond the retroperitoneal lymph nodes 
at disease debut45. A shift towards a higher proportion of seminomas has been observed during 
the last decades , and the seminomas are now slightly more common than non-seminomas46. 
Roughly 40-45% of patients with TC are diagnosed with non-seminomas, and of these 
40-45% will present with metastases in the lymph nodes, the lungs and/or other organs. Non-
seminomas normally affect men in the early-adult life, and are a clinically more aggressive 
GCT43. The histology of non-seminomas are heterogenous, and includes variants of embryonal 
carcinoma, yolk sac tumor, choriocarcinoma, and teratoma. Non-seminomas can consist of a 




In approximately 5% of GCTs the primary site of disease is extra-testicular, i.e. extra-
gonadal germ cell tumors (EGGCTs). These tumors are located in the midline of the body, 
usually in the mediastinum or in the retroperitoneum. The non-seminoumatous EGGCTs have 
poorer prognosis compared with the other GCTs, and EGGCTs originating in the central 
nervous system require treatment  different from the therapy reported hereein47.  
 
1.5 Tumor markers 
The conventional serum protein biomarkers α-fetoprotein (AFP) and human chorionic 
gonadotropin (hCG) are used to assist in diagnostics, treatment response evaluation and 
follow-up assessment of GCTs, but their use is generally restricted to tumors containing the 
relevant biomarker producing malignant subtypes. At diagnosis, roughly 60% of all GCT 
patients, regardless of stage, test positive for these markers; hCG may be increased in 30-35% 
and 10-20% of patients with non-seminomas and seminomas respectively, while AFP is 
increased in 50-60% of non-seminoma patients43. In patients with disseminated disease serum 
hCG and/or AFP are elevated in 85% of cases. Both AFP and hCG are essential in diagnosis, 
prognosis and treatment of patients with germ-cell TC, and should be determined both before 
and after orchiectomy, and during and after further treatment48. Elevated markers pre 
orchiectomy should normalize after orchiectomy in the case of stage I disease, and hCG and 
AFP have half-lives of 1-3 days and about seven days, respectively48. Rising or lack of 
normalization of markers after orchiectomy indicate the presence of metastatic disease. A tumor 
markers decline slower than their half-life during chemotherapy, may indicate treatment 




Serum lactate dehydrogenase (LDH) levels are also used at diagnosis to assist with treatment 
decisions in patients with metastatic NSGCTs, but this marker lacks sufficient specificity to 
be useful in diagnosis or monitoring48. Importantly, only 3% of the TC patients that relapsed 
after a diagnosis of stage I seminoma were identified using standard tumor markers, but 
detection rate was 87% for CT imaging50. 
 Current priorities in GCT research include the identification of novel biomarkers for 
malignant disease, to assist in diagnosis, correct staging and reduce the need for repeated 
cross-sectional CT imaging in follow-up monitoring, hence reducing the associated radiation 
burden and risk of second malignancy development51. Micro-RNAs represent novel 
biomarkers for detecting TC, with a high sensitivity of 86% and a specificity of 92% of miR-
371a-3p52,53. Importantly, miR-371a-3p is expressed both in seminoma and non-seminoma as 





TC treatment is based on the histological diagnosis, tumor marker levels including lactate 
dehydrogenase, and the site(s) of or absence of metastases42. In Scandinavia TCSs are staged 
according to the Royal Marsden Hospital System (RMHS), after orchiectomy (Table 1)54. 
Table 1. Classification of testicular cancer in clinical stages (Royal Marsden)54. 
Stage Disease extensiveness 
I  No detected metastases, either clinically, radiologically, or biochemically 
IMk+ Pathological values of the serum markers AFP and/or hCG beta, without other signs of metastases 
II Lymph node metastases under the diaphragm. The size is measured in horizontal diameter (A<2cm, 
B 2-5 cm, C>5 cm) 
III Lymph node metastases above the diaphragm. (A<2cm, B 2-5 cm, C>5 cm) 
IV Extra lymphatic metastases (most often to the lungs) 
L1 ≤ 3 metastases to the lungs, none > 2 cm 
L2 > 3- ≤20 metastases to the lungs, none > 2 cm 
L3< 20 metastases to the lungs, one or more > 2 cm 
L4 > 20 metastases to the lungs 
 
To decide on the therapy for metastatic TC, three additional prognostic groups were established 
by The international Germ Cell Consensus Classification Group (IGCCCG) (Table 2)55.   
 
Table 2. Definition of the Germ Cell Consensus Classification55. 
Classification Nonseminoma Seminoma 
Good risk Gonadal or retroperitoneal primary tumor 
No non-pulmonary visceral metastases 
Good tumor markers (AFP<1.000 µg/l and 
hCG<5.000 IU/l and LDH<1.5 x Normal) 
Any primary site 
No pulmonary visceral metastases 
Normal AFP, any hCG, and any 
LDH 
Intermediate risk Gonadal or retroperitoneal primary tumor 
No non- pulmonary visceral metastases 
Intermediate tumor markers (AFP 1.000-10.000 
µg/l or hCG 5.000-50.000 IU/l and LDH 1.5-10 x 
Normal) 
Any primary site 
Non-pulmonary visceral metastases 
Normal AFP, any hCG, and any 
LDH 
Poor risk Mediastinal primary tumor or 
Non-pulmonary visceral metastases or 
poor tumor markers (AFP>10.000 µg/l or 





1.7 Treatment principles for TC 
1.7.1	How	the	TC	treatment	has	evolved	through	the	past	half	century	
Half a century ago, limited metastatic TC was treated by surgically removing retroperitoneal 
lymph nodes with bilateral templates [retroperitoneal lymph node dissection (RPLND)]. 5-Year 
survival rates were poor, reaching about 50% during the 1950s. The surgical techniques evolved 
gradually during the 1980s, and today modified nerve-sparing and unilateral surgical techniques 
are used to reduce side effects56-58. Residual vital tumor tissue or teratoma is found in 
approximately one third of retroperitoneal post-chemotherapy non-seminoma lesions <2 cm in 
diameter, despite modern CBCT59. According to the Swedish–Norwegian testicular cancer 
(SWENOTECA) project recommendations, post-chemotherapy RPLND remains important for 
non-seminoma patients with retroperitoneal lesions of 1cm or more, while those under 1 cm 
will be observed if tumor markers are normal.  
Both seminoma and non-seminoma patients with localized disease or retroperitoneal 
lymph node metastases have been treated with radiotherapy (RT) since the 1950s60. Since the 
1980s the prescribed dose and target volumes have decreased gradually, and the treatment 
techniques have improved61,62. Seminoma patients with limited retroperitoneal metastases can 
still benefit from RT today42,63.  
In the 1960s, before cisplatin was introduced as TC treatment, several chemotherapeutic 
drugs were used against metastatic TC, with survival rates of 10-20% for disseminated 
disease64. The introduction of a combination of vinblastine and bleomycin led to an overall 
response rate of 75% including partly durable complete remissions in 32% of the patients65. 
The addition of cisplatin to the regimen of vinblastine plus bleomycin, known as the PVB 
regimen, was introduced by Einhorn and Donohue in the mid-70s. Intriguingly, 5-year survival 
rates reached 64% in patients with metastatic TC66. Aiming to reduce toxicity and increase 
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efficacy, vinblastine was substituted with etoposide during the 80s (known as the BEP 
regimen)64,67. CBCT  is today routinely administered for patients with stage II–IV testicular 
GCTs according to IGCCCG prognostic criteria55, and the BEP regimen is still considered 
as the standard treatment option in first line for disseminated TC68. Active surveillance or 
adjuvant chemotherapy are the typical treatment-options for stage I TC patients in Europe61,62. 
 
1.7.2		Treatment	principles	within	our	study	cohort	(1980‐1994)	
When a testicular malignant tumor is suspected, scrotal ultrasound and tumor markers are 
mandatory. Patients are initially treated with orchiectomy, which is both a diagnostic and 
therapeutic procedure in stage I disease. During the treatment period (1980-1994), which the 
follow-up studies this thesis is based upon, all patients had X-ray or CT of the thorax, and CT 
of the abdomen and pelvis performed after histologically confirmed germ cell TC diagnosis. 
The clinical staging during the treatment time period was performed according to the Royal 
Marsden Staging System (Table 1). 
All men included in both Norwegian follow-up studies [survey I (SI) and survey II (SII)] 
were treated according to the SWENOTECA collaboration69,70 or the European Organization 
for Research and Treatment of Cancer and Medical Research Council protocols71-76. 
 
1.7.3	The	most	common	cytotoxic	agents	used	during	1980‐1994	
In SI and SII, most chemotherapy treated TCSs received an initial regimen with either CVB, 
BEP, or EP (cisplatin in combination with etoposide), with ifosfamid as first line salvage 
therapy. Cisplatin was usually administered ad modum Einhorn, i.e. a dose of 100 mg/m2 over 
the course of 5 days per cycle (daily dose of 20 mg/m²). Within specific research protocols 
cisplatin was given at higher dose intensities (dose-intensive), either with cisplatin above 100 
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mg/m2 per cycle or by administering the same cisplatin dose over less days72,77-79. A strict 
hydration regimen was standard for all CBCT regimen. 
Cisplatin forms cross-links with the cell’s DNA and induces apoptosis80. Its major dose-
limiting acute toxicity is renal damage, which is ameliorated by prophylaxis in the form of high 
fluid administration/intake and furosemide administered when needed. Nausea and vomiting 
represent bothersome side-effects of cisplatin, which are usually avoided by modern antiemetic 
treatment introduced in the 1990s81. Other typical side-effects are neuro- and ototoxicity 
(NTX)82. 
Bleomycin induces DNA strand scissions by free radical actions eventually inducing 
cell death. Bleomycin-induced pneumonitis (BIP) represents its major dose-limiting effect83. 
BIP can ultimately lead to lung fibrosis, by endothelial damage of the lung vasculature due to 
bleomycin-induced cytokines and free radicals. Several studies suggest that the bleomycin 
administration route, dose, higher age, smoking, thoracic radiotherapy, oxygen  rich air 
(ventilation during surgery etc.), and growth factors might increase the risk of BIP83. 
Etoposide, a topoisomerase inhibitor, induces cell death by preventing DNA strand re-
ligation. Its major dose-limiting side-effect is myelosupression84. 
Vinblastine is a vinca-alkaloid which binds to tubulin, thereby inhibiting the assembly 
of microtubules and DNA repair85. Myelosuppression can occur during treatment, and 
neurotoxicity is a prevalent side-effect82. 
Carboplatin is a second-generation Pt compound, acting similarly to cisplatin by 
forming reactive Pt complexes that bind to nucleophilic guanine-cytosin-rich sites in DNA, 
thereby inducing intra- and inter-strand crosslinks. Carboplatin is more chemically stable 
compared with cisplatin, resulting in a lower reactivity with DNA, therefore the doses needed 
to receive equivalent clinical effects are four times higher. With regard to toxicity, carboplatin 
is less nephrotoxic and less emetogenic than cisplatin without relevant neuro- or ototoxicity. 
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Myelosuppression is considered the major toxic effect of carboplatin, particularly 
thrombocytopenia with a nadir usually between day 21 and 2886. 
 
1.7.4	Specific	treatment	of	seminoma	patients	through	1980‐1994	
Infradiaphragmatic radiotherapy was typically given to all men with early-stage seminomas 
(stage I and IIA). Most men received an L-field or dogleg field, involving opposing anterior 
and posterior fields covering the para-aortic and ipsilateral iliac nodes, while a few patients had 
para-aortic fields only87,88. During the 1980s and 1990s the radiation dose for these stages was 
gradually reduced from 36–40 Gy to 25.2–27 Gy89. TCSs with stage ≥IIB were treated with 
CBCT. However, some patients received additional radiation or RPLND. 
 
1.7.5 Specific treatment of non-seminoma patients through 1980-1994 
Until 1990, men with stage I or IIA were treated with a modified bi- or ipsilateral template 
RPLND. Nerve-sparing surgery was introduced in 1989. Adjuvant chemotherapy was given if 
lymph node metastases were present in the pathology specimen69,90. After 1990, patients with 
stage I non-seminomas were either followed closely with radiographic imaging, clinical 
examination and tumor markers (surveillance) or treated with one to three cycles of adjuvant 
chemotherapy70. Patients with disseminated non-seminomas generally received three or more 





2. LATE EFFECTS 
 
2.1 General aspects of cancer survivorship 
Today, the current 5-year relative survival rate for all cancers taken together approximates 70%. 
Given the continuously increasing number of cancer survivors, in-depth investigations of 
treatment-related toxicities affecting health, quality of life and functional status are particularly 
important.  
Most therapeutic modalities for cancer are associated with a wide range of late 
complications, from minor and treatable to serious or, occasionally, potentially lethal 
conditions. Thus, there is today a greater recognition of symptoms that persist after the 
completion of treatment and those that arise years after primary therapy. Long-term side 
effects generally refer to any side effects or complications of treatment that begin during 
treatment and continue beyond the end of treatment. Late effects, in contrast, appear months to 
years after the completion of treatment, and refer specifically to toxicities that are absent or sub-
clinical at the end of therapy and become manifest at a later time-point91.  
Second cancers and CVD represent the most serious late effects. Furthermore TCSs are 
at risk of nephrotoxicity, pulmonary toxicity, NTX, hypogonadism, decreased fertility, and 
psychosocial problems like fatigue and depression4,10,92,93.The debut time and the risk of these 
numerous and different adverse effects vary according to treatment type (chemotherapy, RT or 
both) and intensity. Apart from the treatment burden and some genetic polymorphisms, there is 
still little knowledge about the mechanisms for late effect evolvement, and it is yet not possible 
to identify TCSs at high risk for late effects after TC treatment.  
CBCT is associated with several of the known late effects affecting TCSs, and long-
term Pt residuals have been suggested as a possible late effect biomarker of interest. Platinum 
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retention and typical cisplatin related long-term and late effects studied in this thesis will be 
discussed in detail below.  
 
2.2 Long-term serum Platinum retention after cisplatin treatment 
Platinum is a member of the platinum group elements [PGE, (platinum, pallidum and rhodium)] 
and has six naturally occurring isotopes. It is a very rare metal, occurring mostly in some nickel 
and copper ores in South-Africa94. Pt is considered a noble metal as it is highly inert, even at 
high temperatures, and therefore used in catalytic converters, electrical and jewelry industry, 
laboratory and dentistry equipment. Additionally, platinum is an important compound of the 
platinating cytotoxic agents, such as cisplatin (Figure 4), oxaliplatin and carboplatin.  
Figure 4. The chemical structure of Cisplatin 
 
Of the high cisplatin doses used in TC treatment, only approximately 1% of the cisplatin 
that enters the cells is hydroxylated and binds to the guanine residue of DNA, leading to 
interruption of transcription and apoptosis by bending the double helix95. The remaining 
cisplatin (not associated with DNA) can bind to extra- and intracellular proteins. The first day 
after cisplatin treatment, 30% of cisplatin will be eliminated from the body, while after 5 days 
only 50% of the cisplatin is eliminated96. The elimination half-life of cisplatin may be described 
by numerous half-lives which increases with longer follow-up periods23. Between 120 and 240 
months after cisplatin administration, the half-live has been calculated to be 54 months97. 
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Several studies have shown that with cisplatin-containing chemotherapy, plasma and 
tissue Pt levels are still considerably elevated years after chemotherapy17,23,98. Long-term Pt 
levels are related to time since cisplatin administration, age, dose and glomerular filtration rate 
(GFR). Studies revealed that up to 10% of the retained Pt remains reactive (ex vivo)23. In 2012 
an association between increasing long-term serum Pt levels and increasing severity of neuro- 
and ototoxicity was described, and the assumption that reactive serum Pt several years after 
chemotherapy exposition may contribute to vascular and organ damage was then hypothesized 
for the first time16. 
 
2.3 Neuro- and ototoxicities  
NTX, including peripheral neuropathy (paresthesias), Raynaud's phenomenon, hearing 
impairment, and tinnitus are well-documented cisplatin-related side effects4,16,82,99-101.  
A typical long-term effect  after CBCT is chemotherapy-induced peripheral neuropathy 
(CIPN), developing during or shortly after treatment102. Typically, CIPN presents as a “stocking 
and glove” distribution in feet and hands, due to the vulnerability of the long nerves103. The 
prevalence of CIPN varies from 10 to 100% depending upon the particular anticancer drug, 
drug combination administered and/or the dosing regimen104. After CBCT the prevalence of 
peripheral neurotoxicity is 20-30%82. The exact pathogenesis of long-term CIPN is largely 
unknown, but relatively high Pt levels have been found in the dorsal roots in a post-mortem and 
biopsy study105. Also, the retained serum Pt levels have been found to correlate with the 
administered cisplatin dose16. 
Raynaud’s phenomenon is the most frequent NTX symptom reported by up to 39% of 
TSCs receiving CBCT82,106. Typically, it is a well-demarcated discoloration of the fingers and 
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toes upon exposure to cold, for which bleomycin has been considered the primary causative 
agent107,108. In addition, an association with cisplatin is likely as the incidence of Raynaud-like 
phenomena following chemotherapy for TC increased after the introduction of cisplatin109. 
Furthermore, the risk of experiencing Raynaud’s phenomenon was increased  four-fold for 
TCSs in the highest compared with the lowest Pt quartile for hands (OR, 4.15; 95% CI, 1.60 to 
10.76) and feet (OR, 4.46; 95% CI, 1.70 to 11.71), median 12 years after receiving 
chemotherapy16.  
Cisplatin is one of the most ototoxic drugs in clinical use causing permanent, bilateral, 
sensorineural, high frequency hearing loss in a substantial number of patients110. The reported 
prevalence of hearing impairment in TCSs varies considerably, probably partly due to a lack of 
standardized measurement tools110. The most comprehensive and recent report on hearing 
function among TCSs after CBCT reported almost one in five (18%) patients to experience 
severe to profound hearing loss111. Additionally, many develop permanent tinnitus (40%)82, 
which is demonstrated to be significantly correlated with reduced hearing at each frequency. 
Moreover, 50% of patients receiving a cumulative cisplatin dose of >200 mg/m2 have a 
significant reduction in their hearing, with a severe to profound hearing loss in both ears111.  
Considerable inter-individual variability in susceptibility to cisplatin ototoxicity has 
been described. Other known ototoxic risk factors are: Very young or old, renal failure, pre-
existing hearing loss, noise exposure112,113, nutritional deficiency states (including anemia and 
serum hypoalbuminemia)114, polymorphism of the GST-P1 gene115, and radiotherapy affecting 




2.4 Endocrine-gonadal function  
TCSs are often concerned about their sexual and reproductive function. However, the majority 
of men who have one healthy testicle produce sufficient male hormones and sperm to continue 
sexual relations and father children116. Still, cryopreservation of sperm is recommended prior 
to treatment and in particular before chemotherapy. 
Testicular endocrine dysfunction includes insufficient testosterone production and/or 
compensatory increased luteinizing hormone (LH) levels, also called hypoandrogenism, while 
the exocrine dysfunction gives inadequate spermatogenesis with increased levels of follicle-
stimulating hormone (FSH)26. Usually, the first sign of primary or testicular hypogonadism is 
an elevation of LH level, with subsequent testosterone decline if the LH stimulus is not 
sufficient. A significant rise in LH levels has, in fact, been detected in TCSs treated with 
orchiectomy only117. Several studies have identified long-term hypogonadism after cancer 
treatment, and approximately 50% of the TCSs have levels of sex hormones outside the 
reference range 18 years after treatment5,118. The paternity rate median 11 years after TC 
treatment varied from 81% in the surveillance group to 38% in the high-dose chemotherapy 
group. Overall, 62% of men receiving ≤ 850 mg cisplatin trying for conception became 
fathers119. Higher cumulative cisplatin doses are associated with higher LH levels, 
corresponding to premature hormonal aging5. The degree of both endocrine and exocrine 
hypogonadism is related to treatment intensity120. 
 Intriguingly, more Pt has been shown to be retained by testicles after chemotherapy 
than by other hormone producing organs outside the brain121. However, the high prevalence of 
hypoandrogenism in TCSs may be explained by several factors: Orchiectomy, testicular 




2.5 Cardiovascular disease  
Several European studies have reported 1.4- to 7-fold higher CVD risk among CBCT-treated 
TCSs than in either the general population or in TCSs managed with surgery alone122-125. CVD 
in TCSs typically appears several years to decades after treatment6. Well-documented CVD 
related risk factors like hypogonadism, hypertension, obesity and the metabolic syndrome are 
significantly increased after treatment with CBCT125-127, but the risk is highest for those treated 
with a combination of both RT and chemotherapy125. Mediastinal RT is especially toxic, but is 
no longer applied in TCSs92,125. CVD may be caused in TCSs by a direct vascular damage, e.g. 
an injured endothelium, possibly inducing atherosclerotic processes128. An indirect effect by 
increasing the levels of cardiovascular risk factors has been hypothesized129. Moreover, 
exposure to circulating Pt residuals has been suggested to initiate direct endothelial 
damage124,130, and was for the first time shown to be  associated with several of the most 
prominent risk factors of CVD in 201520.  
Men treated with CBCT have a higher risk of coronary artery disease compared with 
the general population as they age, and should be particularly aware of risk factors such as 
hyperlipidemia, hypertension, obesity, and smoking4. Established risk prediction tools for 
predicting future CVD risk, like the Framingham or SCORE, do not take cisplatin dose into 
account and probably underestimate the true CVD risk after CBCT in TCSs131,132. 
 
2.6 Second cancers  
Second cancer is the leading cause of death among long-term TCSs after treatment with either 
radiotherapy and/or CBCT4. Second cancers after RT are typically located in the former 
radiation field, most often in the stomach, pancreas, kidneys and the urinary bladder133,134.  
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Several publications have demonstrated elevated relative risks for solid second cancers 
after CBCT in most follow-up periods, but particularly with follow-up beyond 20 years135,136. 
Overall, TCSs have a 1.7 to 3.5-fold increased risk of second malignant neoplasms, with a 
significantly increased 40% excess demonstrated for CBCT treated non-seminoma 
patients133,136. 
The rare second myeloid neoplasms occur median 5 years after primary TC treatment, 
and are associated with etoposide dose, with a possible concomitant effect of cisplatin133,137,138. 
Additionally, RT as primary treatment for TC is associated with a 3-fold risk of developing 
leukemia139. 
Patients diagnosed with stage I TC often choose postoperative surveillance as the risk 
for second cancers has not been shown to be increased after orchiectomy alone135. Nevertheless, 
these patients may be at an increased risk for developing second cancer induced by the radiation 
from diagnostic imaging51,140. Therefore, low-dose CT scan or even better, magnetic resonance 
imaging (MRI) has become the standard of surveillance-care in many institutions, and its use 









3. AIMS OF PRESENT THESIS 
 
In 2010 further research to clarify associations between long-term serum Pt and late effects was 
recommended in an international workshop devoted to TCSs24.  Longitudinal studies with 
consecutively assessed data are necessary to understand the associations between CBCT, long-
term Pt change and treatment-related side effects as most published studies have had a cross-
sectional design, with few exceptions16,20. Therefore, the aims of the present thesis were to 
evaluate the associations between serum Pt levels and long-term adverse effects in TCSs at two 
consecutive national surveys with up to 28 years of follow-up.  
Aim 1) To describe the long-term serum Pt levels at SII, according to treatment groups 
(carboplatin, cisplatin>850 mg (cis>850 mg), cisplatin<850 mg (cis<850 mg) and 
orchiectomy), cumulative Pt-based dose and time since therapy in 458 TCSs treated during 
1980-1994 (paper I).  
Aim 2) To investigate the possible associations between long-term serum Pt levels at 
SII with NTX, endocrine-gonadal function and CVD risk factors and events, and the possible 
impact of smoking, in 292 TCSs treated with CBCT received during 1980-1994 (paper II). 
Aim 3) To describe the long-term change in serum Pt levels from SI to SII and to 
evaluate whether the Pt change is  associated with second cancers, renal function and NTX in 






4. MATERIAL AND METHODS 
 
4. 1 The study design and study populations  
The initiation of an unselected large Norwegian follow-up survey which focused on long-term 
treatment-related toxicity was motivated by the growing population of TCSs and the need of 
knowledge regarding their possible side-effects. These two subsequent surveys were conducted 
as Norwegian Urological Study Group (NUCG) studies, and all five university hospitals in 
Norway were involved in these studies. All long-term survivors (n=1,814) of unilateral germ-
cell TC with the age of 18 to 75 years and treated during 1980-1994 were identified through the 
Cancer Registry of Norway and invited to participate. Exclusion criteria were bilateral 
orchiectomy for any reason, extragonadal germ cell cancer, other malignancies except skin 
cancer, and mental retardation. The patients’ medical records were used to find information 
about all oncological treatment including relapse treatment, staging and histology. 
In the first survey, SI (1998-2002), 1463 (81%) consented to participation and had an 
outpatient visit and blood samples drawn and analyzed at the responsible university hospital. 
Deep-frozen serum was stored only for patients at the Norwegian Radium Hospital (NRH) for 
supplementary analyses, including Pt levels.  
Overall 1371 of the men from the first survey were invited to a second follow-up study 
during 2007-2008, SII, where 1093 (80%) participated. A clinical examination was performed 
and blood samples were drawn at the participants’ general practitioner. All the blood samples 
were sent to the Oslo University Hospital for analyses.  
Among the TCSs in SII, 458 men treated with either CBCT or surgery had serum 
available for Pt levels measurements, giving the study population of paper I (Figure 5). A total 
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of 635 TCSs were excluded because they either had ongoing treatment, received RT treatment 
only or they lacked serum for the Pt analyses.  
From the cohort that constituted paper I, we excluded men treated with surgery only, 
leaving 292 TCSs treated with CBCT to define the study population of paper II for investigation 
of Pt relations with late effects. Additionally, we excluded men >60 years at SI because they 
did not have validated CVD information125, and all men lacking questionnaire information 
addressing problems regarding NTX. Two hundred and seventy-five men were assessable for 
hormone analyses in paper II, as 17 men who received testosterone substitution were excluded 
in the analyses of endocrine hypogonadism. 
In paper III we wanted to measure serum Pt in samples from both SI and SII, to elucidate 
the longitudinal serum Pt change in relation with late effects, thus the study size was limited by 
the amount of frozen serum available at SI. As previous research within our research group had 
been performed on the plasma from TCSs, only 77 TCSs previously treated with CBCT and 17 
controls had Pt measurements available at both SI and SII, thus constituting our study cohort in 
paper III. Only samples from NRH patients were frozen at -70ºC. Thus, Paper III involves TCSs 


















4.2 The treatment groups 
All TCSs with advanced disease within this thesis received chemotherapy. Those treated with 
RT alone were considered ineligible. Most men had received treatment with CVB, BEP or EP 
regimens. Overall, two thirds of the 458 men in paper I had RPLND performed, and 41 men 
experienced a relapse. Twenty-four of the 458 TCSs in the cisplatin treatment groups received 
dose-intensive therapy. In addition, 19 men investigated in paper I were treated with 
carboplatin-based chemotherapy within research protocols74-76, of whom five received both 
carboplatin-based and cisplatin-based chemotherapy during their treatment period. In paper II 









































An equivalent amount of carboplatin was throughout this study considered 4-fold less 
potent than cisplatin, conferring to studies based on treatment of ovarian cancer where these 
doses achieved a relative clinical equivalence86,141. For all men throughout this thesis that 
received carboplatin alone or in addition to cisplatin, we calculated their corresponding cisplatin 
dose by dividing their carboplatin dose by four before adding to their cumulative cisplatin dose. 
 In paper I, the individual treatment including relapse treatment established the 
categorization of TCSs into treatment groups: Surgery only (n=135, reference group), 
carboplatin only (n=14), cumulative cisplatin dose ≤850 mg (cis ≤850; n=252) and cumulative 
cisplatin dose >850 mg (cis >850; n=57). In paper II, only men treated with CBCT were 
included and no treatment groups were applied. In paper III, we used the following 
categorization of the TCSs: Controls (surgery only, n=17), and cases (cis≤ 850, n= 52; cis> 850, 
n= 17). 
The cut-off at 850 mg cisplatin was set to separate 1) the TCSs receiving four courses 
or less of standard-dose CBCT from 2) TCSs receiving higher cumulative cisplatin doses due 
to a large number of cycles (progression, relapse or poor prognosis) or treatment with dose-
intensive regimens. Men with a body surface area up to 2.1 m² with maximum four cycles with 
cisplatin-containing regimens were then allocated to the lower dose group, and TCSs who 
received dose-intensive regimens were allocated into the Cis> 850 group, even if they received 
a maximum of four cycles. 
 
4.3 Serum platinum quantification 
From SI and SII, serum samples from 94 and 458 TCSs, respectively, were analyzed for total 
serum Pt at St. Olav University Hospital in Trondheim, using well-established methods23,142. 
The samples were shipped on dry ice from the Oslo University Hospital, and then kept at  




In order to determine the Pt levels, instrumentation with high sensitivity is required. ICP-MS 
is an instrument (Element 2, Thermo Scientific, Bremen, Germany) that consists of two main 
parts: An ion source (ICP) coupled to a mass analyzer (MS). The ion source is a partially 
ionized Argon gas, with very high temperature and electron density. When the sample is 
exposed to this ion source, the chemical bonds are broken and ions are produced. The sample 
ions are transported to the mass analyzer where they are separated on the basis of mass and 
charge. Serum is a complex matrix which makes it necessary to prepare the serum sample 
prior to the analysis with a weak acid. In order to quantify Pt content in the serum sample, the 
instrument is calibrated with a standard containing a certified platinum concentration. A 
relatively simple test and rapid instrumental analysis provide high capacity. ICP-MS has good 
detection properties and is now the preferred technique for determining metal and other trace 
elements in clinical trials. 
 
4.3.2	Reagents	and	standards	
We used doubly distilled concentrated HNO3 and HCl (Chem Scan AS, Elverum, Norway) and 
purified water produced from a MilliQ Element unit (Millipore, France) as reagents and a 
certified standard Pt solution at 1000mg/L (Spectrapure, Oslo, Norway) for preparation of 
calibrators. For the preparation of quality controls we applied oxaliplatin (St. Olav Hospital 
pharmacy, Trondheim, Norway). Both calibrators and controls were prepared by spiking Pt-





We chose a simple dilution of 1+9 as sample preparation to reduce matrix effects and maintain 
detection power. This method is partly adopted from Brouwers et al142. Aliquots of 100µL 
sample were pipetted into clean test tubes (2mL polypropylene, Sarsted, Nűmbrecht, Germany) 
and diluted with 400µL H2O and 500 µL dilution reagent [1% (v/v) HNO3, 1% (v/v) HCl and 
2,000ng Ir/L in H2O]. To provide proper mixing, each test tube was inverted five times. 
 Quality controls and calibrators were prepared by the same method, using Pt-free 
plasma. For external calibration, three calibrators (25, 250 and 1000 ng/l) were produced by 
spiking with the certified Pt solution. Quality controls were prepared at two levels by spiking 
Pt-free plasma with the oxaliplatin solution. A serum sample from a quality management 
program (QMEQAS, Quebec, Canada) with a known Pt value analyzed in every sequence to 
determine the accuracy of the method.  
 
4.3.4	Instrumentation	
The monitoring of Pt was performed in low resolution. A concentric nebulizer and a cooled (5 
°C) cyclonic spray chamber made from PFA-material (ESI, Omaha, USA) and an auto sampler 
(Omaha, USA) constituted the sample introduction system. 
 The 195Pt-isotope was monitored due to its lack of possible spectral interferences and 
high abundance. Internal standardization was used to balance for analytical issues. For this, 193Ir 
was chosen, and we applied it at a final solution of 1,000 ng/L to all samples and calibrators. 
 To ensure optimal daily instrument performance, a solution containing 1,000 ng/L of 
indium, uranium and barium were used. Instrument settings were tuned to give typically 
readings like 115In: 1.5 x106 cps (counts per second), 238U: 2.0 x106 cps, and production of BaO+ 
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Limit of quantification (loq) was calculated from 10 times the standard deviation of a series of 
blanks. Pt was analyzed in batches for SI and SII, with a time interval of approximately four 
years between the analyses, hence loq was calculated for SI and SII separately. The loq level 
for this method was 15 ng/l in SII and 13ng/l in SI. Serum Pt below loq was set to zero for both 
surveys. Linearity was proved for the concentration range from 15 to 10,000 ng/L. Based on 
quality control samples, inter-sequence precision in low level and high level were estimated to 
9.9% and 5.1% in SII and 7.7% and 5.9% in SI, respectively. Intra-sequence precision in low 
level (100 ng/L) and high level (1,000 ng/L) were estimated to 3.6% and 1.2%, respectively.  A 
serum sample from a quality management program gave mean values corresponding to a 
consensus value 143. 
 
4.4 The questionnaires and neuro-ototoxicity assessment  
In both surveys the questionnaires (see appendix) addressed several aspects of somatic and 
psychosocial health in long-term TCSs. It contained questions about social status, physical 
activity, comorbidities, medication use and smoking habits, and the information of such was 
based on self-report. If questions where left blank, individuals with missing data were 
categorized as healthy (comorbidities), without treatment (medication use) or missing (physical 
activity and smoking), respectively. All CVD information was validated125, and overall eight 
men had missing NTX information from SI (paper III). 
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Additionally, the questionnaires included a validated six-item scale for chemotherapy-
induced neurotoxicity (SCIN) addressing neuropathy (paresthesias) in hands and feet, Raynaud-
like phenomena in hands and feet, tinnitus, and impaired hearing. The symptom scores ranged 
from zero (not at all), one (a little), two (quite a bit) to three (very much) (Table 3). Adding the 
six symptoms generated a total SCIN score ranging from zero to 18. The total SCIN score were 
categorized into four groups of similar size (quartiles), according to increasing symptoms 
(paper II). In the third paper, change within the six individual SCIN symptoms was categorized 
into three groups according to if the symptoms were decreasing, stable or increasing during the 
time-period from SI to SII. 
Table 3. Scale for chemotherapy-induced neuro-oto-toxicity (SCIN) 










Have you suffered from pain and/or tingeling 
in your hands/fingers? 
0 1 2 3 
Paresthesias 
feet/toes 
Have you suffered from pain and/or tingeling 
in your feet/toes? 
0 1 2 3 
Raynaud’s 
hands/fingers 
Have you suffered from numb or cold 
hands/fingers? 
0 1 2 3 
Raynaud’s 
feet/toes 
Have you suffered from numb or cold 
feet/toes? 
0 1 2 3 
Tinnitus Have you suffered from ringing in your ears? 0 1 2 3 
Impaired 
hearing 
Have you suffered from reduced hearing? 0 1 2 3 
 
 
4.5 Assessments and definitions 
In both SI and SII, resting blood pressure was measured with an automatic device or manually. 
Blood samples were drawn by venipuncture before 11 AM at the university hospital’s outpatient 
clinic or at the TCSs general practitioners office, for SI and SII respectively, for assessments of 
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blood lipids, glucose, LH, testosterone, creatinine and serum Pt. The blood samples were drawn 
in a fasting state only in SII. In SII, all routine blood samples were analyzed at Oslo University 
Hospital to reduce the variation coefficient, since poor reproducibility of steroid hormones 
measurements has been observed144. Total testosterone and LH were determined using a 
commercial immunoassay.  
In paper I, the serum Pt levels were categorized into quartiles to evaluate the risk of 
being in the highest quartile according to the four different treatment groups mentioned above.  
In paper II, the same categorization into quartiles of Pt levels as in paper I was 
performed, to assess associations with different late effects according to higher Pt levels.  
Levels of testosterone and LH from 599 controls were obtained from the Nordic 
reference interval project, and categorized into one to four with respect to cutoff values for the 
25, 50 and 75 percentiles within each decadal age group145. To assess associations between Pt 
and disturbed endocrine gonadal function (endocrine-GF), testosterone and LH levels in 275 
TCSs were assigned to one of these four categories, based on the percentiles derived from the 
reference group.  
Also, in paper II CVD was defined as ischemic heart disease [angina and myocardial 
infarction (MI)], stroke or artery occlusion. CVD risk factors like hypertension, obesity, and 
metabolic syndrome were defined by the National cholesterol education program criteria 
(NCEP)146. Diabetes was defined as previously diagnosed diabetes based on information 
retrieved from the questionnaires or a serum glucose ≥ 11 mmol/l. Smoking status was defined 
as never, previous or current smoker.  
In paper III, Pt change was defined as (Pt at SI minus Pt at SII)/ per year. Since most 
men had a Pt decline, the Pt change was called a Pt decline throughout paper III. All information 
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about second cancers after SII was retrieved from the Norwegian Cancer Registry updated 
December 31st, 2015. Only one man with a second cancer (malignant melanoma, diagnosed 
1998) prior to SI was excluded from these analyses, as we wanted to address the relationship 
with the Pt change observed between SI and SII, considering the late effects.  
Furthermore, in paper III, in line with a similar long-term Pt retention and late effect 
study in TCSs, serum creatinine was dichotomized at ≤ or >90 µmol/l20.  
In paper III, the smoking status was defined differently, according to if analyses were 
in relation with second cancers or NTX. Within the second cancer analyses smoking was 
defined as never, earlier or current smokers at SII, with never smokers as reference group. For 
NTX analyses, smoking habits were categorized in four groups; never, earlier, or current 
smokers (reference group) reported in both surveys (SI and SII), and stopped smoking between 
SI and SII. Within this paper the physical activity was defined as low, middle or high, with high 
as reference level, in line with previous publications19,147. 
 
4.6 Statistical methods 
All p-values were two-sided and statistical significance was set at P< 0.05. The data were 
analyzed by using IBM SPSS (SPSS, Chicago, IL) statistics version 21.0 for both paper I and 
II and version 24.0 for paper III. 
Categorical variables were presented as counts and proportions, and continuous 
variables were presented as median (range). The Mann-Whitney U test was used to compare 
median values of serum Pt or Pt change across different groups since the Pt levels were not 
normally distributed. Simple associations between continuous variables were analyzed with 
either Pearson correlation, Spearman’s rank, or simple linear regression. The χ2 test was used 
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to test associations between categorical distributions. Additionally, Pt levels were visualized 
with scatter plots.  
Ordinal logistic regression (OLR) models were used to evaluate the risk of having serum 
Pt in the highest quartile according to treatment group, with the surgery group representing the 
reference group (paper I). Similarly, in paper II, the risk of having serum Pt in the highest 
quartile according to intensity of the toxicity of interest (separate symptom scores for NTX and 
the total SCIN score, or endocrine-GF) was assessed with OLR. OLR models assessed 
associations between both Pt change and cisplatin dose as the explanatory factors and all six 
SCIN symptoms in SII or with NTX change observed from SI to SII as dependent variables in 
paper III. Model assumptions in all the ordinal logistic regression models were checked by a 
test of parallel lines. 
Cox proportional hazard regression models were used for analyzing the associations of 
serum Pt and cumulative cisplatin with respect to CVD incidence, with the observation time 
registered from the date of TC diagnosis until the date of first CVD event of interest or until the 
date of SII ( paper II). Cox proportional regression models were also applied to analyze the risk 
of a second cancer diagnosis after SII according to Pt change from SI to SII and Pt levels at SII, 
with the observation time registered from the date of orchiectomy until the date of diagnosis of 
a second cancer, or until December 31st 2015 (paper III). In paper III, the analyses only included 
two variables because of the rule of ten events per variable in Cox regression models148. Visual 
inspection of log minus log of survival curves was used for model assumption in all Cox 
regression models.  
Overall, data were presented as odds ratios (OR) or Hazard ratios (HR) with 95% 
confidence intervals (CIs), and both ordinal regression and Cox proportional hazard regression 
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models included administered cumulative cisplatin and age, as they were considered of high 
importance clinically.  
 
4.7 Approvals 
The Committee for Medical Research Ethics, the Southern Health Region of Norway, approved 
both of the surveys (S-98094 and S-07305b, for SI and SII, respectively) and the additional Pt 
studies presented in this thesis (2015/1630). All participants gave informed written consent for 




















In SI (N=1463), the non-responders were not different from responders with respect to age at 
follow-up, histology, stage or treatment. Because of our exclusion criteria (not allowing men 
treated with RT only and men >60 years at SI) the 458 men participating in paper I had 
somewhat lower age at disease debut, longer follow-up time, and higher TC stages compared 
with the 1093 men participating in SII.  
 
5.1 Paper I 
Long-term platinum retention after treatment with platinum-based chemotherapy in testicular 
cancer survivors: A 20-year follow-up study. (Anticancer Research 2015) 
This paper describes the serum Pt levels according to treatment and follow-up time in 458 TCSs. 
The TCSs were categorized into four treatment groups: Surgery (n=135), carboplatin (n=14), 
cis≤850 mg (n=252) and cis>850 mg (n=57). The observation time was from 16 to 20 years 
(range 13-28) for all, and the majority of men had non-seminoma (87%). Overall, 51% had 
metastatic disease at the diagnosis.  
The median Pt level for the cis≤850 group 85 ng/L (0-725), the cis>850 group 106 ng/L 
(21-247), the surgery group was 50 ng/L (range 0-230) and for the carboplatin group 40 ng/L 
(0-1140). Pt levels were positively associated with cisplatin-treatment groups (p<0.001) and 
cisplatin dose (p<0.001), and negatively associated with follow-up time (p<0.001). We did not 
reveal associations with Pt levels and carboplatin treatment (p=0.18).                                                
 The odds for having Pt in the highest quartile was positively associated with 
cumulative cisplatin dose (OR 1.29, 95% CI 1.20-1.38 per 100 mg increase in cisplatin dose). 
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Additionally, the cisplatin treatment groups were associated with an increased risk of having 
serum Pt in the highest quartile with an OR at 9.4 (cis≤850: 95% CI 3.9-22.5) and an OR at 
31.2 (cis>850: 95% CI 11.6-84.1), compared with the surgery group.  
In conclusion, this paper documented that TCSs previously treated with CBCT have increased 
Pt levels up to 28 years after receiving treatment, when compared with controls. Pt was also 
detectable among some men treated with surgery alone. 
 
5.2 Paper II 
Associations between long-term serum platinum and neuro- and ototoxicity, endocrine gonadal 
function and cardiovascular disease in testicular cancer survivors. (Urologic oncology 2016). 
In this paper, 292 CBCT treated TCSs were included to evaluate the serum Pt measured at SII 
median 19 years after chemotherapy, and its impact on NTX, endocrine gonadal function, and 
CVD. Approximately 80% of the TCSs received 3-4 cycles of CBCT. 
Herein, we documented that increasing serum Pt quartiles was significantly associated with 
increasing quartiles of total SCIN score (P for trend=.05), increased hearing impairment (P=.04) 
and increased tinnitus (P<.001). All associations attenuated when cisplatin were added in the 
OLR-models. 
Importantly, current smokers had significantly increased intensity of paresthesias in 
hands (OR 2.85, 95% CI; 1.60-5.06), feet (OR 1.76, 95% CI; 0.99-3.14), and Raynaud’s 
phenomenon in hands (OR 2.50, 95% CI; 1.43-4.39) and feet (OR 2.42, 95% CI; 1.37-4.28) in 
multivariable OLR models including cisplatin dose, serum Pt and age .  
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The OR for being in the highest quartiles of LH increased with an increase in quartiles 
of serum Pt. The OR for being in a higher LH quartile was 2.50 (95% CI 1.28–4.87) for the 
third serum Pt quartile. The cumulative cisplatin dose was positively associated with higher LH 
levels (OR 1.17, 95% CI 1.06-1.30 per 100 mg cisplatin). No significant associations between 
quartiles of testosterone and serum Pt levels were established. 
 No significant associations between any of the risk factors for CVD and serum Pt levels 
were discovered.  
In conclusion, increasing quartiles of long-term serum Pt are associated with increasing 
SCIN score, tinnitus, hearing impairment and increasing LH levels. However, these 
associations were attenuated when adjusted for cumulative administered cisplatin dose, and 
persisted only for tinnitus and LH. 
 
5.3 Paper III 
Long-term platinum change and its associations with cisplatin-related long-term and late 
effects in testicular cancer survivors. (Submitted to Acta oncologica, March 2018) 
A total of 77 CBCT treated men (cases) and 17 controls (TCSs treated with surgery) had serum 
Pt levels evaluated at both SI (median 12 years after CBCT) and SII (median 20 years after 
CBCT) in order to describe the Pt change over time, and to evaluate the associations between 
serum Pt change between SI and SII and second cancers, renal function and NTX in cases.  
While the median Pt levels of the controls were 0 ng/L at both surveys, the median Pt 
level for all cases was 75 ng/l (0-377) and 64 ng/l (0-725) at SI and SII, respectively. In this 
paper most men experienced a decline of Pt levels from SI to SII [4.2 ng/l/year (range – 93 to 
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+27)]. However, 11 (14%) of cases experienced increasing Pt from SI to SII. The cumulative 
cisplatin dose was associated with a Pt decline (r = 0.30, p = 0.01). 
After SII, 12 cases (15%) had a second cancer diagnosis. At SII, a higher Pt level was 
associated with an increased risk for a second cancer diagnosis (HR 1.22, 95% CI 1.05-1.42 per 
50 ng/L increase in Pt), while a larger Pt decline from SI to SII was associated with decreased 
risk of a second cancer diagnosis (HR 0.78, 95% CI 0.62-0.99 per 10 ng/L/year). Interestingly, 
the current smokers, when compared with never smokers, had an increased risk of a second 
cancer (HR 9.14, 95% CI 1.88-45.0).  
The serum Pt levels were higher among cases with creatinine >90µmol/L in SI for the 
cis>850 treatment group (p=0.05), compared with cis>850 with creatinine <90µmol/L. The 
creatinine level at SI and SII was positively associated with the cumulative cisplatin dose 
(r=0.25, p=0.03 and r= 0.24, p=0.04, respectively. Multivariable analyses with Pt levels, late 
effects and creatinine did not reveal any significant associations. 
All six NTX symptoms had significantly increased severity from SI to SII (p<0.001 for 
all). NTX change analyses showed that men with a larger Pt decline from SI to SII had a 
significantly higher risk of increasing paresthesias in hands (OR 1.98, CI 1.09-3.59, per 10 
ng/l/year) and tinnitus (OR 1.51, CI 1.01-2.27, per 10 ng/L/year). These findings remained 
significant when adjusting for cisplatin dose. Patients who stopped smoking between SI and SII 
or never smoked had a lower risk of deteriorating Raynaud’s phenomenon, compared to current 
smokers. 
In conclusion, after adjusting for age and administered cumulative cisplatin dose, an 
increasing Pt decline from SI to SII was associated with a decreased risk for a second cancer, 
but with worsening of paresthesias and tinnitus from SI to SII. 
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6. DISCUSSION  
 
6.1 Methodological considerations  
6.1.1	General	aspects		
This study evolves from two cross-sectional follow-up studies, in which outcomes were 
evaluated between 1998-2002 (SI) and 2007-2008 (SII), whereas the cytotoxic treatment was 
administered several years before (1980-1994).  
  Cross-sectional studies, also called prevalence studies, are observational and can be 
useful to detect differences between groups149. As we have used data from two cross-sectional 
studies performed at different time points, we have the possibility to interpret the associations 
between Pt levels and late effects longitudinally (paper III). Longitudinal studies are considered 
highly valid for determining long-term changes, and their primary advantage is to detect 
patterns that occur over long periods. Thus, the present thesis can be seen to some extent as a 
retrospective cohort study with regard to the late effect outcomes. Retrospective studies often 
need large sample sizes for evaluating rare outcomes, and there is a risk of selection bias, 
information bias and confounding150. 
 
6.1.2	Internal	and	external	validity	
It is important to consider both external and internal validity when interpreting a clinical 
study150. External validity refers to whether the study generates a valid hypothesis applicable to 
a more general clinical population. For this study, all TCSs treated in Norway during 1980-
1994 were retrieved from the Norwegian Cancer Registry and cross-checked with the university 
hospital databases, and the eligible study population was considered complete. Both studies on 
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which the present thesis is based had approximately 80% response rates. Moreover, all 
participants were treated according to international guidelines with limited variety, thus the 
external validity is considered to be acceptable for this study. The TC treatment has changed 
since 1980-1994. However, the standard treatment for most men with disseminated TC today 
is still considered to be 3-4 cycles of BEP. The results presented in this thesis are still valid for 
current TCSs and the doctors/ health personnel involved in treatment and follow-up of these 
patients. 
The internal validity, random and systematic errors (bias), refers to how a clinical study 
can produce valid results150. The random errors are due to chance and can be minimized by 
increasing the sample size or reducing measurement variations. Herein we have critically few 
TCSs for grouping according to treatment for especially the CVD analysis in paper II. CVD 
occurs late in life, most incidents after the age of 60.Thus our participants with median age of 
49 at survey II, would probably need a larger population to be able to demonstrate any 
relationship between exposure and outcome. Studies with few participants have higher risks for 
incorrectly accepting the null hypothesis (type II error)149. In paper III, only 77 men treated 
with CBCT had available serum for Pt analyses in both surveys, which hampers the ability to 
draw reliable conclusions149. 
Herein we have applied numerous statistical tests, with the possibility of incorrectly 
rejecting the null hypothesis only due to chance (type I error). In exploratory and 
epidemiological studies where a final conclusion might not be necessary nor possible, 
corrections for multiple testing are not considered compulsory. In such studies the Bonferroni 
test may be inappropriate, as it will be highly conservative and analyses may miss real 
differences151,152, and we have chosen to not make any corrections. 
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Any errors influencing the study participation (selection bias) or distortion when 
collecting information about participants (information bias) are referred to as systematic 
biases150. Such biases reflect any deviations that leads to conclusions which may systematically 
over- or under-estimate the associations between exposure and outcome.  
 
6.1.3 Selection bias 	
Selection bias occur when participation is hampered by the selection of either individuals, 
groups or data for analysis149. This may lead to various association between outcome and 
exposure for responders and non-responders.  If some groups of the eligible population is less 
likely to be included than others it is defined a sampling bias150. This type of bias may create a 
sample which is unrepresentative of the population intended to be analyzed. 
 In our study, all TCSs treated during 1980-1994 were invited, and participation was 
voluntarily, with insignificant differences between responders and non-responders according to 
stage, age, histology or treatment. It can be argued that people participating in medical research 
are healthier and more motivated compared with those who do not participate153. Since we  lack 
information about the non-respondersʼ level of late effects, we can only speculate whether the 
participants in the study are compared to the non-responders150. Nevertheless, the participation 
rate was high in both surveys, hence minimalizing the risk of selection bias. 
 In paper II and for late effect analyses in paper III, only TCSs with prior chemotherapy 
were included. Additionally, the cohorts included in all papers in the current thesis were 
restricted by available frozen serum, which had been used for several previous studies, thereby 
introducing a possible selection bias. In paper III, only patients with serum samples frozen at 
both surveys were eligible, and this was limited to patients treated at only one hospital (the 
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Norwegian Radium Hospital). During the treatment period, this hospital was main hospital for 
cancer treatment in Norway, increasing the possibility of including patients with more intensive 




Information bias (observational bias) occurs when measurement or classification of information 
about the study participants is incorrect. Non-differential misclassification refers to when an 
exposure variable has the same probability of being misclassified for all subjects, regardless of 
outcome. Differential misclassification refers to when the misclassification of exposure differs 
for study participants according to outcome status150.  
In paper II and III, smoking status and physical activity are based on self-reported 
information retrieved from the questionnaires. In issues where strong personal feelings can be 
a source of bias, for example with smoking habits and physical activity, data may be incorrectly 
reported to reduce a person’s feelings of guilt, with a risk of information bias (social desirability 
bias)154. In paper II, only self-reported information about incident CVD in the questionnaire 
were validated, with a probability of underestimating both the true incidence of CVD and 
associations between exposure (cisplatin dose, Pt level) and CVD.  
Misclassification of symptoms regarding self-reported NTX may also exist. However, 
a report comparing audiograms with self-report of hearing impairment has shown high 
correlation, and the SCIN is recommended as a brief screening instrument for chemotherapy 
induced neuro-oto-toxicity155. Additionally, the SCIN score represents a clinical relevant 
measure, addressing to which extent the symptoms affect quality of life. 
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Most of the patients had blood samples collected before 11.00 a.m., to assure similar 
conditions regarding hormonal analyses, due to diurnal variations of testosterone5. 
Measurements of testosterone may differ between laboratories, however, in paper II the 
variability of testosterone is considered to be acceptable since all hormonal analyses was 
performed at the same laboratory. 
To minimize possible measurement errors when assessing Pt levels, only one laboratory 
performed all analyses with a method partly adopted from Brouwers et al142. For evaluation of 
the Pt measurement accuracy, a standardized serum sample from a quality management 
program was analyzed in every sequence. To ensure optimal instrument performance, 
instrument settings were tuned and adjusted daily. 
 
6.1.5	Confounding	 
Confounding refers to a variable that influences both the independent and the dependent 
statistical variable causing a distortion or confusion of effects. Confounding can be statistically 
reduced by stratification or adjustments in multivariate analyses149. 
The prevalence of most of the late effects which we have studied, increases with age. 
This includes CVD, neuropathy, tinnitus and hearing impairment as well as cancer and 
endocrine hypogonadism156-159. Since age was a possible confounder it was necessary to adjust 
all outcome analyses for age. Additionally, in the multivariate analyses concerning late effects 
and serum Pt levels we adjusted for the cumulative cisplatin dose, since all late effects studied 
in this thesis are associated with CBCT. 
Another possible confounder was smoking, which is a well-known risk factor for CVD, 
neuropathy and cancer160-162. Consequently, we included smoking status when we performed 
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all ordinal and cox regression models involving these outcomes to explore the effect of 
smoking. 
Of note, when addressing Raynaud’s phenomenon, most patients in the study also 
received bleomycin, which is considered the main cytotoxic causative agent82. Hence, 
confounding of the associations between cisplatin and Raynaud’s phenomenon by bleomycin 
is a possibility in our study. 
 
6.2 Discussion of results  
6.2.1	 Long‐term	platinum	 levels	 at	 SII	 and	platinum	 level	 change	 from	 SI	 to	 SII	
(paper	I	and	paper	III)	
In paper I, we showed that Pt levels are higher in TCSs treated with cisplatin up to 28 
years after chemotherapy compared with patients treated with surgery only.  In agreement with 
previous research, we detected significant association between Pt levels and cumulative 
cisplatin dose as well as time since treatment16,17,23. Besides, as reported in paper III, although 
most men had a decline of Pt during follow-up, 14% of the TCSs showed a Pt increase. 
 For Pt level quantification, we utilized ICP-MS, a highly sensitive technique partially 
adopted from Brouwers et al142. The susceptibility of the procedure is due to both the instrument 
performance and the sample preparation. To avoid interference and minimizing the 
contamination risk, we diluted the serum specimens to reduce the concentration of organic 
matrix, hence maintaining a high sensitivity and detection power. For measuring total Pt levels, 
the signal from the195Pt isotope can be a subject to interference of signals from hafnium oxides. 
In ICP-MS conditions, this metal oxide observation is typically insignificant and within our 
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study the detected signal of hafnium was low in all samples, which made further improvements 
redundant. 
Surprisingly, our surgery treated controls had higher Pt levels compared with data from 
both Sprauten et al (personal communication), Gietema et al. and Brouwers et al16,17,23. This 
may be the result of different analytical methods and specimens, environmental factors, or 
incomparable genetic susceptibility, which all theoretically may influence the Pt levels in men 
not exposed to cisplatin.  
The observed increase in Pt levels from SI to SII among 14% of cases in paper III may 
possibly be explained by Pt exchange between compartments with diverse pharmacokinetics, 
as Pt residuals has been found in most organs after chemotherapy121. This theory is supported 
by a demonstration of retained Pt pharmacokinetics resembling lead, which stores within bone 
with the possibility to be released into the circulation21. In addition, the observed increase in Pt 
levels in some cases may in part also be explained by a higher exposure to PGE pollution. 
The serum Pt levels in our Norwegian male controls (blood samples drawn 2007-2008) 
was high compared with blood levels in Italian healthy adolescents (from 2009), with median 
values at 50ng/L and 9.87 ng/l, respectively163. Biomonitoring studies have shown that the 
body burden levels of PGE reflect the exposure to elevated concentrations of these noble 
metals, with higher exposure and uptake among urban populations and those working in close 
proximity with traffic164. In a German study, Pt concentrations in airborne particulate matter 
were found to be six times higher for samples collected in 2008–2010 compared to 2002165, 
and inhalation of PGE-containing particulate matter are believed to be the most important 
exposure route for Pt in humans166. Importantly, the worldwide production of PGEs has 
increased significantly since the 1970s because a more prevalent use of vehicle exhaust 
catalysts94. High levels of PGE in soil bordering heavy trafficked areas are well 
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documented167,168. Pt typically occurs as an insoluble metal and is the least soluble PGE, 
solubility ranging from 1.4-19% for gasoline-powered engines and from 2-7% for both new 
and aged diesel powered engines165. In Norway, approximately 80% of the population is living 
in urban communities, where the soluble Pt of roadside dust is high. An explanation for the 
lower Pt levels reported in earlier studies23,169 may be that the investigated populations were 
assesed in a period with less PGE pollution and accumulation. 
A genetic difference between the Dutch and the Norwegian cohorts might explain the 
difference in median Pt levels. Various gene expressions have been linked with chemotherapy-
induced toxicities99,115, and it remains to estimate if genetic polymorphisms can generate 
heterogeneous pharmacokinetics and chemotherapy tolerance among patients.  
From our data, no relationship between Pt levels and long-term follow-up time for 
carboplatin treated TCSs could be established, probably due to the limited number of patients. 
Additionally, levels of Pt is shown to be artificially low in carboplatin treated patients after 
serum storage temperatures at -20º C170, comparable to our study. To the best of our knowledge, 




In paper II we found that cumulative administered cisplatin doses remained associated 
with NTX, while associations between long-term Pt levels and NTX symptoms diminished over 
time16,19. Additionally, we found associations with Pt levels at SII and higher LH-levels, but no 
associations with CVD. In paper III we found that a larger Pt decline from SI to SII was 
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associated with a decreased risk for second cancer and an increased risk for tinnitus and 
paresthesias in hands. 
Sensory neuropathy, Raynaud’s phenomenon, tinnitus and hearing impairment are well-
known neurotoxic side effects of cisplatin with a prevalence of 30% to 40% in TCSs, with a 
potential negative impact on their quality of life82,108. These side effects are related to both 
cumulative cisplatin dose and treatment intensity171,172. Our findings in paper II partially 
corroborated the results demonstrated in 2012 by Sprauten et al16. Compared with our study, 
the Sprauten study, which to some extent was based on the same TCSs cohort as our study, 
demonstrated a stronger association between all NTX symptoms and retained Pt median 12 
years after CBCT. In their study, the cumulative cisplatin dose was not associated with neither 
total SCIN score nor individual SCIN symptoms in multivariate OLR analyses. Possibly, our 
seven year longer follow-up with subsequently lower Pt levels, less dose-intensive treatments 
and differences in ICP-MS methodology can partly explain a diminished association between 
the Pt levels and NTX when cisplatin dose was included in our statistical models.  
The exact pathogenesis of long-term CIPN is largely unknown. Results of several post-
mortem studies show that Pt is retained and stored in essentially all organs, such as lungs, 
kidneys, liver, muscle, bone and skin121,173,174. Furthermore, Pt levels measured within nerves 
are typically highest in dorsal root ganglia and lowest in the brain105. Whether the cumulative 
amount of cisplatin correlates with Pt levels in the dorsal roots is, however, not known. It has 
been hypothesized that continuous exposure to low-level serum Pt on neural tissue contributes 
to ongoing damage16. In paper II, the diminished association between serum Pt levels and SCIN 
symptoms, when cisplatin was added to our multivariable OLR models, suggests that the 
treatment burden has a stronger effect on NTX development than the Pt residuals. In paper III, 
we demonstrated that a larger Pt decline from SI to SII correlated positively with higher 
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cumulative cisplatin doses, and was additionally associated with a higher intensity of 
paresthesia (hands). Taken together, since cisplatin-induced peripheral neuropathy (CIPN) 
typically develops during or shortly after treatment102, we hypothesize that it is more likely that 
CIPN are associated with the administered cisplatin dose rather than the long-term Pt exposure 
or Pt decline.  
In paper II, tinnitus remained significantly associated with long-term Pt when adjusting 
for cisplatin dose. Additionally, in paper III, we found that a larger Pt decline was associated 
with an increase in tinnitus from SI to SII. Previous studies have shown that 40–80% of adults 
and at least 50% of children are left with permanent hearing loss after receiving CBCT, when 
including frequencies outside normal speaking range111,175. Chemotherapy-induced ototoxicity 
is mainly ascribed to cisplatin, which is believed to cause inner ear damage trough loss of outer 
hair cells in the organ of Corti, leading to tinnitus and hearing impairment176. If Pt stored in 
nerves is related to ear function and/or the cisplatin-induced initial damage during treatment is 
responsible for outer hair cell dysfunction, are yet to be investigated. Further knowledge was 
recently proposed by showing that cisplatin accumulation in mice and human cochlea is 
consistently high in the stria vascularis, the region of the cochlea that maintains the ionic 
composition of endolymph. Moreover, the authors demonstrated prominent amounts of 
cisplatin levels in the long bones21. Similar to lead, Pt can be distributed into bone and be 
exchanged back into the blood, with a half-life of years-to-decades177. The major protein 
component of bone, type I collagen, binds to Pt, from which it slowly dissociates178. Hence, the 
cochlear bone is suggested to function as a reservoir for Pt, leading the long-term destruction 
of cochlear and bone cells, a possible premise for the ototoxicity caused by cisplatin21. Whether 
the prolonged release of Pt from bone can mediate the late toxicities of cisplatin, needs further 
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investigation. As far as we know, there is still no documented substance that may relieve the 
neurotoxicity of platinating agents 179,180. 
Hypogonadism can cause a diversity of complications for TCSs, such as fertility 
problems, muscle weakness, reduced sexual functioning and psychological problems116,181-183. 
It is also associated with conditions like decreased bone mineral density, obesity, CVD 
development and the metabolic syndrome125,126,129,184. Corresponding with our results, an 
increased risk of premature hormonal aging with higher LH levels has been significantly 
associated with administered cumulative cisplatin dose5,120. Additionally, in paper II, increased 
Pt levels were associated with increasing LH levels after CBCT, supporting previous findings20. 
In a post-mortem study, testicles retained more Pt after CBCT compared with other endocrine 
organs outside the brain121. Hypothetically, the endocrine hypogonadism observed in long-term 
TCSs can be due to ongoing damage of the testicles, possibly due to continuous exposure to 
residual Pt. 
The increased risk of potentially life-threatening CVD in TCSs is a major complication 
of CBCT, mediastinal radiotherapy and even subdiaphragmatic radiotherapy122-125,185,186, with 
an increased risk for CVD several years after treatment termination6. Inflammation and 
endothelial dysfunction are essential components in the development of atherosclerosis, on both 
short- and long-term. CBCT has been demonstrated to activate the atherosclerotic 
process128,187,188. Pt residuals have been measured in TCSs up to median 20 years after 
CBCT17,18, additionally 10% of the serum Pt remain reactive median 41 months after 
treatment23. Hence, CVD after CBCT is hypothesized to partially be the result of ongoing 
endothelium damage caused by the raised long-term Pt levels, as well as increased CVD risk 
factor levels. Recently. Boer et al. demonstrated associations between Pt exposure and both 
CVD risk factors, paresthesias and hypogonadism. They assessed a pharmacokinetic model for 
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Pt exposure which included cisplatin dose, age, weight, and height along with Pt levels20, but 
their subsequent statistical models did not include cisplatin dose. Thus, elucidation of the effect 
of cisplatin dose is still lacking. In paper II, we demonstrated an association between CVD and 
cumulative cisplatin dose only, but statistical power was hampered by few CVD events in our 
cohort.  
The most prominent cause of death among long-term TCSs after cytotoxic treatment is second 
cancers4. Numerous studies have shown an elevated relative risk for solid second cancers, 
especially with follow-up beyond 20 years133,135,136. The cancer sites registered in our cohort 
corroborates with a Danish study reporting increased risks for cancers in the lung and bladder 
among others. However, our cohort is not large enough to calculate relative risks for further 
comparison135. Nevertheless, in paper III, we are the first to show a relationship between a 
larger decline in Pt levels and a reduced risk of having a second cancer, whereas the 
cumulative cisplatin dose was not associated with the risk of second cancer. We hypothesize 
that Pt storage and pharmacokinetics might be just as important as the cisplatin dose itself for 
very late effects after cancer treatment, such as second cancers. 
Decreased renal function after TC treatment is closely related to an increased number 
of BEP cycles and the accumulated doses of cisplatin, but the reported changes in GFR are 
partly reversible and have no impact on CVD risk or associated death189-191. Nevertheless, renal 
function, both prior to and shortly after CBCT, was found to be associated with long-term 
exposure to circulating Pt in the study of Boer et al20. In paper III, we demonstrate a significant 
association between Pt levels at SI and creatinine at SI. However, no association between Pt 
decline and creatinine levels was demonstrated, probably due to our limited study population.  
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Smoking has been shown to cause damage in most organs192,193, and is a considerable 
risk factor for different cancers194,195. In paper II we found a strong association between 
smoking and neurotoxicity in TCSs, similar to previous studies performed after CBCT82. In 
paper III we demonstrated that current smokers at SII, when compared with never smokers, had 
a major increased risk of developing a second solid cancer. Additionally, we saw that men who 
never smoked and men who quit smoking between SI and SII had a lower risk of Raynaud’s 
symptoms increasing, confirming earlier studies which report smoking to be an important 




7. CONCLUSIONS AND IMPLICATIONS FOR FUTURE 
RESEARCH  
 
In paper I, we were the first to document that TCSs previously treated with CBCT have 
increased Pt levels up to 28 years after CBCT, compared with those treated with surgery only 
(control group). Their Pt levels were positively associated with the cisplatin dose and inversely 
associated with follow-up time. Additionally, we found that our controls had relatively high 
levels of platinum, when compared with healthy controls in PGE biomonitoring studies. In 
paper II, we present the longest follow-up time published so far for Pt retention in CBCT treated 
TCSs and associations with NTX, endocrine–GF and CVD. Tinnitus and increasing LH-levels 
were positively associated with higher Pt levels after adjusting for cisplatin dose. In paper III, 
we found that the Pt decline from SI to SII in 77 TCSs previously treated with CBCT, was 
associated with worsening of NTX and a reduced risk of second cancer. 14% of TCSs had 
increasing Pt levels from SI to SII. 
Further studies with respect to late effects are needed to clarify underlying mechanisms 
and to explore associations with serum Pt. We suggest larger prospective studies including 
evaluation of Pt elimination rates, storage and excretion, to elucidate their consequences for 
long-term effects in TCSs. Of note, the relationship between residual long-term Pt and the more 
life threatening toxicities, like second cancers and CVD, needs to be prioritized in larger studies 
with follow-up periods beyond 20 years. 
Prophylaxis studies have not been able to document any substances that prevent the 
neurotoxicity of platinating agents179,180. We hope that future studies with focus on detoxifying 
agents will be performed, which hypothetically can prevent all possible late effects associated 
with Pt exposure. 
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 Genes associated with Pt detoxification should be elucidated to further understand the 
individual differences observed with respect to late toxicity. Knowledge about the inter-
individual vulnerability after CBCT may be clinically important in risk-adapted follow-up of 
TCSs in the future. We suggest a further exploration of the relationship between cisplatin 
related late effects and genetics.  
The high Pt levels in surgery treated TCSs (paper I), along with the observed increasing 
Pt levels for some of our TCSs (paper III), and possible disease associations, especially second 
cancers, should be investigated further. Airborne particulate matter, which is associated with 
PGEs, has been associated with an increased incidence of morbidity and mortality in exposed 
urban populations197,198. Whether environmental Pt exposure contributes to the associations 
between Pt levels and the medical problems included in this thesis remains to be evaluated. 
Regarding clinical relevance, we interpret the associations between late effects and 
smoking to be helpful in the follow-up of all TCSs treated with CBCT, with smoking cessation 
as a high priority. Careful follow-up of TCSs is necessary to quantify and possibly prevent the 
long-term risks of these survivors. We suggest focusing on improving unfavorable life style 

































































































































































































































































































































































































































































































































































Etterundersøkelse av pasienter behandlet for testikkelkreft
Vi ber deg om å fylle ut dette spørreskjemaet så godt du kan ved å krysse av det svaret som passer.
Svar på alle spørsmål, selv om det noen gang kan virke slik at vi spør om det samme i flere spørsmål.
Alle svar behandles konfidensielt.
kgVekt:cmHøyde:
. .Dato for utfylling:
       dag        måned              år
Pasient nr.:
















1. a) Hva er din nåværende arbeidssituasjon? (sett kun ett kryss X ved det svaret som passer)
ARBEID OG UTDANNING
    b)  Hvis arbeidsledig, sykemeldt, eller pensjonist, er kreftsykdommen årsak for at du for tiden ikke er i arbeid?
Hvis nei, oppgi alternativ grunn:
Grunnskoleutdanning (10-årlig grunnskole -tidl. 9-årig, 7-årig folkeskole eller lignende)
Videregående utdanning (Allmennfag, yrkesskole eller annet)
Fagutdanning / yrkesutdanning / fagbrev / videregående yrkesfaglig utdanning
Universitets- /høgskoleutdanning med inntil 4 års varighet
Universitets- /høgskoleutdanning med mer enn 4 års varighet
2.  Sett kryss ved det yrkesområdet som best beskriver arbeidet ditt.  Dersom du for tiden ikke er yrkesaktiv, oppgi det
     yrkesområdet du sist har hatt. (sett kun ett kryss X)
2007 Testis
29834
Kontor for klinisk forskning, RR-HF2 / 13
Ja Nei
3.  Har kreftsykdommen hatt innvirkning på dine muligheter til å få den utdanning som du ønsket eller planla før du fikk kreft?
4. a) Har du noen gang skiftet arbeidsplass?
Ja Nei








6.  Har kreftsykdommen virket inn på din mulighet for å delta i opplæring knyttet til yrkesfaglig utvikling som arbeidsplassen
     har arrangert?
Ikke aktuelt
Ikke i det hele tatt
I noen grad
I stor grad
Hvis Ja: Kan du spesifisere hvorfor/hvordan kreften førte til at du skiftet arbeidsplass?
Hvis Ja: Kan du spesifisere hvorfor/hvordan kreften førte til at du skiftet yrke?
Hvis Ja, antall ganger:
5. a)  Har du noen gang skiftet yrke?
Ja Nei Hvis Ja, antall ganger:
7.  Har kreftsykdommen hatt innvirkning på dine muligheter til å oppnå en forbedret situasjon på jobben?
Ikke aktuelt






Kontor for klinisk forskning, RR-HF3 / 13
Pasient nr.:
8.  Har kreftsykdommen noen gang ført til at du har blitt utsatt for noen av disse hendelsene?
Ikke i det
hele tatt









9.  Mener du at din arbeidsevne er blitt nedsatt på grunn av kreftsykdommen?





10. La oss gå ut fra at arbeidsevnen din på sitt beste ville fått 10 poeng.  Hvor mange poeng vil du da gi din nåværende
     arbeidsevne?  (0 innebærer at du i dag ikke er i stand til å arbeide i det hele tatt.  Sett kryss ved det tallet som du mener
     best tilsvarer din nåværende arbeidsevne).
0 1 2 3 4 5 6 7 8 9 10
11. Tror du diagnosen og behandlingen av testikkelkreft har hatt negativ innflytelse på din nåværende
      arbeidssituasjon/utdanningssituasjon?
Ja Nei
Hvis Ja, på hvilken måte?
12. Hvordan er helsen din nå?





Kontor for klinisk forskning, RR-HF4 / 13
13. Har du noen langvarig (minst 1 år) sykdom, skade eller lidelse av fysisk eller psykisk art som nedsetter din funksjon i ditt
      daglige liv?
Ja Nei
14. I hvilken grad har din fysiske helse eller eventuelle følesesmessige problemer begrenset deg i din vanlige sosiale omgang
      med familie eller venner i løpet av de siste 4 uker?
Ikke i det hele tatt En del Litt Mye




Hemmet pga kroppslig sykdom
Hemmet pga psykisk sykdom
Hvis Ja, hvor mye vil du si at dine funksjoner er nedsatt?
Middels   Mye
Pasient nr.:
HELSETJENESTER
16. Har du vært innlagt på sykehus i løpet av de siste 12 måneder:
Ja Nei
Årsak og hvilket sykehus:
Fastlege/allmennlege
Annen legespesialist utenfor sykehus
Konsultasjon uten innleggelse
- ved psykiatrisk poliklinikk




håndspålegger, eller annen alternativ
behandler
15. Har du i løpet av de siste 12 måneder vært hos:
Ja          Nei
2007 Testis
29834
Kontor for klinisk forskning, RR-HF5 / 13
17.  Har du i løpet av de siste 5 år vært hos psykolog/psykiater?
Ja Nei
RØYKING
Her ønsker vi å kartlegge all din bruk av tobakk.  Vi har derfor delt inn i et hovedspørsmål om daglig røyking, og et
spørsmål om "røyking av og til".
19. a) Har du noen gang røykt daglig?
Ja Nei
     b) Røyker du for tiden daglig?
Ja Nei
     c) Hvis du har røykt daglig tidligere, hvor lenge er det siden du sluttet?
Antall år
     d) Hvis du røyker daglig nå eller har røykt daglig tidligere: Hvor mange sigaretter røyker eller røykte du vanligvis daglig?
Antall sigaretter
     e) Hvor mange år til sammen har du røykt daglig?
Antall år
HVIS NEI - GÅ TIL SPØRSMÅL 20
Pasient nr.:
18.  Har noen av disse kontakt med helsevesenet hatt relasjon med din testikkelkreft sykdom?
Ja Nei Ikke aktuelt
     c) Hvis du røyker av og til eller har røykt av og til tidligere: Hvor mange sigaretter røyker eller røykte du vanligvis i løpet av en
         måned?
Antall sigaretter
21. Røyker du pipe/sigar?
20. a) Har du noen gang røykt av og til?
Ja Nei
     b) Røyker du for tiden av og til?
Ja Nei
Ja Nei
HVIS NEI - GÅ TIL SPØRSMÅL 21
Hvis Ja: Pakker pipetobakk per måned:
eller: Antall sigarer per måned:




Kontor for klinisk forskning, RR-HF6 / 13
AKTIVITET
22. Hvordan har din fysiske aktivitet i fritida vært det siste året?  Tenk deg et ukentlig gjennomsnitt for året.
      Arbeidsvei regnes som fritid.
SYKDOMMER OG PLAGER
I noen av de følgende spørsmål ber vi deg oppgi alderen din da eventuell sykdom inntrådte.
Hvis du ikke husker nøyaktig hvor gammel du var, skriver du et tall som er nærmest det du antar er korrekt.
Kryss av for det svaret som passer, og sett kun ett kryss.
DIABETES
23. Har du fått påvist diabetes (sukkersyke)?
Ja Nei
   a) Hvis Ja: Hvor gammel var du da din diabetes ble oppdaget? år
   b) Hvis Ja: Bruker du insulin (sprøyter, penn) mot din diabetes nå? Ja Nei
   c) Hvis Ja: Bruker du tabletter mot din diabetes? Ja Nei
BLODTRYKK
24. Har du brukt eller bruker du blodtrykksmedisin?
Ja, nå Ja, tidligere Nei, aldri
   Hvis Ja: Hvor gammel var du første gang du begynte med slik medisin? år
            Timer per uke
ingen    under 1     1-2            3
Lett aktivitet (ikke svett/andpusten):
Hardere fysisk aktivitet (svett/andpusten):
Pasient nr.:
HJERTE/KAR-SYKDOMMER
25. Har du hatt hjerteinfarkt?
Ja Nei
   a) Hvis Ja: Hvor gammel var du første gang du fikk hjerteinfarkt? år
   b) Hvis Ja: Hvor mange ganger har du hatt hjerteinfarkt? Antall ganger
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26. Har du eller har du hatt angina pectoris (hjertekrampe)?
Ja Nei
   a) Hvis Ja: Hvor gammel var du da du merket slike hjertekramper første gang? år
   b) Hvis Ja: Hvor mange ganger per uke har du merket slike smerter i løpet av den siste måneden? Antall ganger
   c) Ved anstrengelse: ganger/uke
   d) Når du er i ro om dagen: ganger/uke
e) Om natten: ganger/uke
27. a) Har du fått behandling for angina pectoris med tabletter?
Ja Nei
Navn på tabletter og hvilken
lege / evt. sykehus startet behandlingen?
b) Har du blitt hjerteoperert med nye blodårer til hjertet (bypass-ACB)?
Ja Nei
Hvilket sykehus?
c) Har du blitt blokket/fått innsatt stent i blodårene på hjertet?
Ja Nei
Hvilket sykehus?
28. Har legen sagt at du har hjerteflimmer (atrieflimmer)?
Ja Nei
29. Har legen sagt at du har hjertesvikt (svakt hjerte, vann på lungene, hovne ben)?
Ja Nei
30. Har du noen gang fått påvist forsnevring på hovedpulsåren i hals eller mage, eller fått påvist trange blodårer i bena?
Ja Nei
Hvis Ja, spesifiser hvor forsnevringen satt
Hvilket årstall ble dette påvist?
Pasient nr.:
31. Har du noen gang hatt blodpropp i bein eller lunge?
Ja Nei
Hvis Ja, vennligst spesifiser hvor
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HJERNESLAG / HJERNEBLØDNING
32. a) Har du hatt TIA ("drypp") eller symptomer på hjerneslag som gikk fullstendig tilbake innen 24 timer?
Ja Nei
   Hvis Ja: Hvor gammel var du da du hadde det første gang? år
   Hvis Ja: Hvor mange ganger har du hatt det? Antall ganger
NYRESYKDOMMER
33. Har det noen gang blitt påvist nedsatt nyrefunksjon hos deg?
Ja Nei
   Hvis Ja: Hvor gammel var du da dette ble påvist første gang? år
Hvis Ja, spesifiser på hvilken måte den
nedsatte nyrefunksjonen ble oppdaget
(egghvite eller blod i urinen, blodprøve)
Astma




Ny kreftsykdom ETTER testikkelkreften






34. Har du, eller har du hatt:





      b) Har du noen gang hatt hjerneslag (blodpropp eller blødning i hjernen)?
Ja Nei
   Hvis Ja: Hvor gammel var du da du hadde hjerneslag første gang? år
   Hvis Ja: Hvor mange ganger har du hatt hjerneslag? Antall ganger
29834
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TANNHELSE
35. Når var du sist hos tannlegen?






Mer enn 6 år siden
Aldri
36. Har du vært hos tannlegen regelmessig (minst 1 gang i året) de siste 5 år?
Ja Nei
Ingenting (har ikke vært hos tannlegen)
Ingenting (har fått kostnadene dekket)
Mindre enn 500 kroner
501 - 1000 kroner
1001 - 3000 kroner
3001 - 5000 kroner
5001 - 15000 kroner
Mer enn 15000 kroner
37. Hvor mye har du til sammen betalt hos tannlegen i løpet av de siste 12 månedene?
38. Har du fått refundert noen av dine tannlegeutgifter pga munntørrhet etter kreftbehandlingen?
Ja Nei
Undersøkt tenner (med ellen uten røntgenbilder)
Renset tenner/fjernet tannsten
Plombert/fylt hull i tenner






Fått råd om renhold av tenner
Tannkjøttbehandling
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40. Har du hatt noen av de følgende problemer med munnhulen ETTER kreftbehandlingen?
 
41. Hvordan vurderer du din munn-og tannhelse?
a) Hull i tennene - nedslitte tenner









  dårlig God
Meget
  god
SMERTER/PLAGER (i løpe av den siste måneden)
(sett et kryss X ved det som passer)
42. Er du plaget av smerter, stikninger eller
      nummenhet i hender/fingre?
43. Er du plaget av smerter, stikninger eller
      nummenhet i føtter/tær?
44. Er du plaget av hvite/kalde hender/fingre når det
      er kaldt?
45. Er du plaget av hvite/kalde føtter/tær når det er
      kaldt?
46. Er du plaget av øresus?
47. Er du plaget av nedsatt hørsel?
48. Er du plaget med smerter i muskler og ledd?
49. Har du i løpet av det siste året vært plaget med
      smerter og/eller stivhet i muskler og ledd som
      har vart i minst 3 måneder sammenhengende?
50. Er du plaget av kvalme?
51. Er du plaget av brystbrann/sure oppstøt?
52. Er du plaget av diaré/løs mage?
  Ikke i
det hele
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MEDISINBRUK
53. Har du i deler av det siste året brukt noen medisiner/behandlinger daglig eller nesten daglig?
Ja Nei
SOSIAL OG ØKONOMISK SITUASJON





55. Antall barn under 18 år i din husstand:
      Hvorav under 7 år:
56. Hva er for tiden husstandens forventede årsinntekt før skatt (inntekt fra selvstendig og næringsvirksomhet, lønn og pensjon)?












1 000.000 eller mer










Annen medisin, spesifiser antall mnd
Behandling for impotens, spesifiser antall mnd
Antall måneder i løpet av det siste året
Navn:







Dette spørreskjemaet er utformet for å hjelpe oss til å forstå hvordan du føler deg.  Les hvert utsagn og sett kryss
       x i ruten som best beskriver dine følelser den siste uka.  Fundér ikke for lenge på ditt svar; din umiddelbare
                  reaksjon på hvert spørsmål er sannsynligvis riktigere enn et svar som du har tenkt lenge på.
2. Jeg gleder meg fremdeles over ting jeg pleide å
    glede meg over
Avgjort like mye
Ikke fullt så mye
Bare lite grann
Ikke i det hele tatt
 3. Jeg har en urofølelse som om noe
     forferdelig kommer til å skje
Helt sikkert og svært ille
Ja, men ikke så veldig ille
Litt ille, men det bekymrer meg ikke så mye
Ikke i det hele tatt
 4. Jeg kan le og se det morsomme i situasjoner
Like mye som jeg alltid har gjort
Ikke like mye nå som før
Avgjort ikke så mye nå som før
Ikke i det hele tatt




En gang i blant





 7. Jeg kan sitte i fred og ro og kjenne meg




Ikke i det hele tatt
 8. Jeg føler meg som om alt går langsommere
Nesten hele tiden
Svært ofte
Fra tid til annen
Ikke i det hele tatt
 9. Jeg føler meg urolig liksom jeg har
     sommerfugler i magen
Ikke i det hele tatt
Fra tid til annen
Ganske ofte
Svært ofte
10. Jeg har sluttet å bry meg om hvordan jeg ser ut
Ja, helt klart
Jeg bryr meg ikke så mye som jeg burde
Det kan nok hende jeg ikke bryr meg nok
Jeg bryr meg om utseendet like mye som jeg alltid har gjort
11. Jeg føler meg rastløs som om jeg stadig må
      være i aktivitet
Uten tvil svært mye
Ganske mye
Ikke så veldig mye
Ikke i det hele tatt
12. Jeg ser med glede frem til hendelser og ting
Like mye som jeg alltid har gjort
Heller mindre enn jeg pleier
Avgjort mindre enn jeg pleier
Nesten ikke i det hele tatt
13. Jeg kan plutselig få en følelse av panikk
Uten tvil svært ofte
Svært ofte
Ikke så veldig ofte
Ikke i det hele tatt
14. Jeg kan glede meg over en god bok eller et
      radio eller et TVprogram
Ofte
Fra tid til annen
Ikke så ofte
Svært sjelden




Ikke i det hele tatt




Vi vil gjerne vite om du har følt deg sliten, svak eller i mangel av overskudd den siste måneden.  Vennligst besvar
 ALLE spørsmålene ved å krysse av  x  for det svaret du synes passer best for deg. Vi ønsker at du besvarer alle
  spørsmålene selv om du ikke har hatt slike problemer. Vi spør om hvordan du har følt deg i det siste og ikke om
   hvordan du følte deg for lenge siden. Hvis du har følt deg sliten lenge, ber vi om at du sammenlikner deg med
                                                         hvordan du følte deg sist du var bra.
 
                                                                     (Ett kryss på hver linje)
1.     Har du problemer med

















3.     Føler du deg søvnig eller









4.     Har du problemer med

















6.     Har du redusert styrke i









7.     Føler du deg svak? Mindre enn
vanlig




8.     Har du vansker med å
        konsentrere deg?
Mindre enn
vanlig




9.     Forsnakker du deg i









10.   Er det vanskeligere å









11.   Hvordan er









12.   Hvis du føler deg sliten for tiden, omtrent hvor lenge har det vart?
Seks måneder eller merMellom tre og seksmånederMindre enn tre månederMindre enn en uke
13.   Hvis du føler deg sliten for tiden, omtrent hvor mye av tiden kjenner du det?
Hele tiden75% av tiden50% av tiden25% av tiden
Fatigue (tretthet)
EORTC QLQ-C30
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Pasient nr.:
TAKK FOR HJELPEN!
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